Baird Downgrades Harpoon Therapeutics (HARP) to Neutral

Baird analyst Colleen Kusy downgraded Harpoon Therapeutics (NASDAQ: HARP) from Outperform to Neutral with a price target of $1.50 (from $8.00).

For an analyst ratings summary and ratings history on Harpoon Therapeutics click here. For more ratings news on Harpoon Therapeutics click here.

Shares of Harpoon Therapeutics closed at $0.79 yesterday.

You May Also Be Interested In

• Canaccord Downgrades York Space Systems (YSS) to Hold, 'Supply chain and contract timing uncertainty'
• Freedom Broker Upgrades PrimeEnergy Resource (PNRG) to Hold
• Central Retail Corp PCL (CRC:TB) PT Lowered to THB9,000 at Macquarie